Not insisting on board seat; only an investor: Thyrocare's A Velumani

I am an investor, and not insisting on any board seat. I am selling my entire stake of 66 per cent, says Velumani

PharmEasy’s parent API Holdings last week announced the acquisition of a majority stake in Thyrocare for Rs 4,546 crore. In an interview to Sohini Das, Thyrocare Chairman A Velumani says while the decision to exit was five years old, he did not wish to get into a desperate deal and refutes speculation that a lack of succession planning induced the sale. He also talks about his journey of building the company, and why omni-channel services are the thing of the future. Edited excerpts:

Why did you decide to sell your entire stake in Thyrocare?

A proposal came and the valuation was high.